[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639156":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":87,"collaborators":24,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":24,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":24,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":114,"whyStopped":24,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"inulin (prebiotics)","EXPERIMENTAL","The intervention dose is 10 grams per day. The intervention will last for 4 months.",[13],"Dietary Supplement: inulin (prebiotics)",{"label":15,"type":16,"description":17,"interventionNames":18},"maltodextrin","PLACEBO_COMPARATOR","The intake dose is 10 grams per day for 4 months.",[19],"Dietary Supplement: Placebo Comparator: maltodextrin",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT",[9],null,{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Placebo Comparator: maltodextrin","The dose is 10 grams per day for 4 months.",[15],[30],{"name":31,"affiliation":5,"role":32},"An Pan","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},"Yuxia Wei, PhD","CONTACT","86-18813185223","2026020052@hust.edu.cn",{"name":40,"role":36,"phone":41,"phoneExt":24,"email":42},"An Pan, PhD","86-18186123783","panan@hust.edu.cn",[44,56,64,74,79],{"facility":45,"status":24,"city":46,"state":47,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":24},"The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture","Enshi","Hubei","China","CN",{"type":51,"coordinates":52},"Point",[53,54],109.48333,30.3,{"lat":54,"lon":53},{"facility":57,"status":24,"city":58,"state":47,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":63,"contacts":24},"Sinopharm Dongfeng General Hospital","Shiyan",{"type":51,"coordinates":60},[61,62],110.77806,32.6475,{"lat":62,"lon":61},{"facility":5,"status":24,"city":65,"state":47,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Wuhan",{"type":51,"coordinates":67},[68,69],114.26667,30.58333,{"lat":69,"lon":68},[72,73],{"name":35,"role":36,"phone":37,"phoneExt":24,"email":38},{"name":40,"role":36,"phone":24,"phoneExt":24,"email":42},{"facility":75,"status":24,"city":65,"state":47,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":76,"geoPoint":78,"contacts":24},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"type":51,"coordinates":77},[68,69],{"lat":69,"lon":68},{"facility":80,"status":24,"city":81,"state":47,"zip":24,"country":48,"countryCode":49,"cosmosGeoPoint":82,"geoPoint":86,"contacts":24},"Xiangyang No.1 People's Hospital","Xiangyang",{"type":51,"coordinates":83},[84,85],112.14479,32.0422,{"lat":85,"lon":84},{"type":32,"investigatorFullName":31,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Professor","100639156","effects-of-inulin-on-cardiometabolic-risk-factors-in-individuals-using-glucagon-like-peptide-1-receptor-agonists-glp-1-ra--medications-for-weight-loss-100639156",false,"NCT07611552","Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss","The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial","Inclusion criteria:\n\n* Be overweight or obese (meeting any of the following criteria):\n\n  1. Obesity: BMI \\>=28 kg\u002Fm²;\n  2. Overweight (BMI \\>= 24 kg\u002Fm²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease.\n* Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months.\n* Age 18-64 years.\n* Consent to participate and sign the informed consent form.\n\nExclusion criteria:\n\n* Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months;\n* Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt);\n* Be allergic or intolerance to inulin-type substances;\n* Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials;\n* Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding;\n* Deemed unsuitable for participation by the investigator's judgment.","ALL","18 Years","64 Years",{"count":100,"type":101},600,"ESTIMATED","INTERVENTIONAL",[104],"NA","The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.",[107],"Obesity & Overweight",[109,110,111,112,113],"weight loss","cardiometabolic risk factors","prebiotics","lipids","glucagon-like peptide-1 receptor agonists (GLP-1 RA)","NOT_YET_RECRUITING","2026-06-01",{"date":117,"type":118},"2026-06-03","ACTUAL",{"date":120,"type":101},"2026-06",{"date":122,"type":101},"2026-11",{"name":5,"class":6},5]